NCT00083707已完成2 期
UARK 99-006, A Phase II Pilot Study of Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 2
- 主要终点
- To determine tumor response, overall and progression free survival following thalidomide therapy in patients with Waldenstrom's Macroglobulinemia (WM)
研究概览
简要总结
The purpose of this research is to study how helpful thalidomide is in controlling the disease and to study any side effects from taking thalidomide.
详细描述
Patients will receive thalidomide in the oral form each night before bed. The dose of thalidomide will be increased each week until week 7 as long as there are no significant side effects.
Routine physical examinations and blood tests will be done to monitor the effect of treatment and the toxicities encountered, if any, and provide the available treatments for side effects accordingly. Blood tests will be done to monitor the tumor response.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have a confirmed diagnosis of previously treated, active Waldenstrom's Macroglobulinemia
- •Patients must have adequate hematologic function as demonstrated by total white blood count > or = 2000/mm3, adequate renal function as demonstrated by serum creatinine < or = 3.0 mg/dl, and adequate hepatic function as demonstrated by bilirubin < or = 1.5 mg/dl and transaminases < or = 4 x ULN
- •All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
排除标准
- •No other concurrent therapy for WM is permitted while on thalidomide
- •Pregnant or nursing women may not participate. Before starting treatment, women of childbearing potential should have a negative pregnancy test performed within 24 hours prior to beginning therapy. Written report of a negative pregnancy test must be obtained before a prescription for thalidomide is issued. Women/men of reproductive potential may not participate unless they have agreed to use an effective contraceptive method. Pregnancy testing is not required for 1) women who have been post-menopausal for at least 2 years with no menses, 2) women who have had a hysterectomy.
结局指标
主要结局
To determine tumor response, overall and progression free survival following thalidomide therapy in patients with Waldenstrom's Macroglobulinemia (WM)
次要结局
- To determine toxicities associated with thalidomide in patients with Waldenstrom's Macroglobulinemia
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Anti-Angiogenesis Therapy Using Thalidomide in Multiple MyelomaMultiple MyelomaNCT00083577University of Arkansas250
已完成
3 期
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation ChemotherapyMultiple MyelomaNCT00083551University of Arkansas668
已完成
2 期
Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory LeukemiaLeukemiaNCT00083694University of Arkansas25
Unknown
4 期
A Study of Thalidomide in the Treatment of Refractory Uremic PruritusHaemodialysisUremic PruritusThalidomideNCT05525234RenJi Hospital40
终止
2 期
Safety and Efficacy Study of Thalomid in Patients With Chronic PancreatitisChronic PancreatitisNCT00469703Winthrop University Hospital10